Story first appeared in Reuters.
Abbott Laboratories Inc will pay $1.6 billion to resolve civil and criminal allegations that it promoted anti-seizure drug Depakote for uses that were not approved by U.S. health regulators, the company and federal and state officials said on Monday.
The diversified healthcare company has agreed to plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act for misbranding, and to enter into a Corporate Integrity Agreement with the U.S. government that will oversee Abbott's compliance program for five years.
Charleston Defective Drug Lawyers say that this was an intentional, systematic marketing policy by the company, this was not the product of some rogue sales representatives who in some field office on their own went and engaged in off-label marketing.
The settlement is the second-largest payment by a pharmaceutical company and resolves the Depakote matter with the federal government, as well as 49 states and the District of Columbia.
Pfizer Inc in 2010 agreed to pay $2.3 billion in a similar settlement over marketing practices with its drugs.
Under terms of the settlements, Abbott will pay $800 million to resolve state and federal civil charges, a $700 million criminal penalty and $100 million to states to resolve consumer protection matters.
Abbott was accused of promoting the drug for unapproved uses, including to control agitation and aggression in elderly patients who suffered from dementia and to treat schizophrenia, despite the absence of credible scientific evidence that Depakote was safe and effective for that use.
Additionally, the civil settlement resolves allegations that Abbott offered money and in some cases paid healthcare professionals and pharmacies to encourage them to promote and prescribe the drug, Salt Lake City Defective Drug Lawyers said.
Abbott said it had previously set aside the funds in anticipation of the settlement, which relates to a four-year-old investigation of Depakote sales and marketing practices dating back to 1998 and running through 2006.
While doctors are free to prescribe drugs any way they see fit, drugmakers are only allowed to promote them for uses approved by the U.S. Food and Drug Administration, according to Indianapolis Defective Drug Lawyers.
Abbot has stated that they are pleased to resolve this matter and are confident that the have the programs in place will satisfy the requirements of this settlement.
In addition to the large payments, Abbott agreed to several other measures, including a five-year corporate integrity agreement in which the company's board of directors will have to review and certify the effectiveness of its compliance program.
The company will also be required to post online information about any payments it makes to doctors.
The case emerged in part from whistleblowers who filed lawsuits against Abbott. Those whistleblowers will receive $84 million from the federal government's share of the settlement, according to the Justice Department.
Abbott plans to split into two companies later this year with the branded drugs business going by the name AbbVie.
For more healthcare and medical related news, visit the Healthcare and Medical
For national and worldwide related business news, visit the Peak News Room blog.
For local and Michigan business related news, visit the Michigan Business News blog.
For law related news, visit the Nation
of Law blog.
For real estate and home related news, visit the Commercial and
Residential Real Estate blog.
For technology and electronics related news, visit the Electronics America blog.
For organic SEO and web optimization related news, visit the SEO Done Right blog.